Viatris

Last updated

Viatris Inc.
Company type Public
ISIN US92556V1061
Industry
Predecessors
FoundedNovember 16, 2020;3 years ago (2020-11-16)
Headquarters
Canonsburg, Pennsylvania
,
U.S.
Area served
Worldwide
Key people
  • Scott A. Smith (CEO)


Products
RevenueDecrease2.svg US$15.39 billion (2023)
Decrease2.svg US$766 million (2023)
Decrease2.svg US$54.7 million (2023)
Total assets Decrease2.svg US$47.69 billion (2023)
Total equity Decrease2.svg US$20.47 billion (2022)
Number of employees
c. 38,000 (2023)
Subsidiaries
Website viatris.com
Footnotes /references
[1]

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. [2]

Contents

The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community. [3] [4]

Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. [5]

History

On November 16, 2020, Upjohn merged with Mylan in a Reverse Morris Trust transaction and changed its name to Viatris. [1] [2] At that time, Michael Goettler became chief executive officer. [6] [3]

Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS. [2]

In December 2020, the company announced a cost-reducing restructuring plan that would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world. [7] [8] [9]

In 2021, Viatris was ranked 5th by Fortune on its annual "Change the World" list for having "transformed the treatment of HIV around the world in the [previous] five years through the first low-cost antiretroviral drug for first-line treatment of HIV and a children's version in the form of fruit-flavored tablets that dissolve in liquid. [10]

In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. [11] The transaction was completed in November 2022. [12] In November 2022, the business agreed to acquire Oyster Point Pharma and Famy Life Sciences for an aggregate of $700–750 million to create an ophthalmology division. [13] [14] The acquisitions closed in January 2023. [15] [16]

In 2022 and 2024, Viatris was recognized by Forbes as one of the world's best employers [17] and by Newsweek as one of America's most responsible companies. [18] [19]

On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. [20]

In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, [21] and one of the 25 best companies offering career development in Ireland. [22]

In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. [23]

In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. [24]

In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion. [25]

Predecessors

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Viatris Acquisitions
  • Viatris
    • Merger of Mylan and Upjohn
    • Famy Life Sciences (Acq 2023)
    • Oyster Point Pharma (Acq 2023)

Products

Viatris Pharmaceutical Plant in Istanbul. 27 may 2023. Viatris Pharmaceutical Plant in Istanbul, Ortakoy.jpg
Viatris Pharmaceutical Plant in Istanbul. 27 may 2023.

The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. [26] It owns brands (like Viagra, Xanax, Lipitor), [6] [27] generics, including branded and complex generics, biosimilars, [28] [29] and over-the-counter (OTC) drugs and active pharmaceutical ingredients. Viatris products cover therapeutic areas including cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology. [29] [30]

The following products have been newly launched or received regulatory approvals since Viatris was established include:

Partnerships

Following the formation of Viatris, the company became a member of the Biosimilars Forum, a trade organization that advocates for greater biosimilar usage. [28]

Viatris partnered with the American College of Cardiology, the NCD Alliance, and the World Heart Federation to create the NCD Academy, a platform to help fight non-communicable diseases around the world. [40] [41]

In December 2020, the company worked with Sesame Workshop to create resources to help children and their caregivers manage their social and emotional needs impacted by the COVID-19 pandemic. [42] [43]

In April 2021, the company partnered with Atomo Diagnostics and Unitaid to expand access to HIV self-testing to 135 countries and lower the price of the tests by around 50%. [44] [45]

In February 2024, Viatris entered into an agreement with Idorsia to collaborate on global research and development and the commercialization rights to Phase 3 pharmaceuticals selatogrel, a cardiac medication, and cenerimod, a novel immunology medication used to treat systemic lupus erythematosus. The agreement includes the potential to add more assets in the future. [46] [47] [48]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Upjohn</span> Pharmaceutical manufacturing firm

The Upjohn Company was an American pharmaceutical manufacturing firm founded in 1886 in Hastings, Michigan, by Dr. William E. Upjohn who was an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. They could be "reduced to a powder under the thumb", a strong marketing argument at the time.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Heather Bresch</span> American business executive

Heather Bresch is an American business executive. In 2012, she was named as the chief executive officer (CEO) of Netherlands-based pharmaceutical company Mylan, becoming the first woman to run a Fortune 500 pharmaceutical company. Bresch retired in 2020, upon the closing of Mylan’s combination with Upjohn. Bresch has been a central figure in two controversies: a 2007 accusation of inflating her resume with an unearned MBA degree, and as the CEO of Mylan during the 2016 controversy over pricing of the company's EpiPen products. In 2015, she was listed as #22 in Fortune magazine's “Most Powerful Women” list.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

References

  1. 1 2 "Viatris Inc. 2023 Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 28, 2024.
  2. 1 2 3 Gough, Paul J. (November 16, 2020). "After nearly 60 years, Mylan makes way for Viatris". American City Business Journals .
  3. 1 2 "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette . November 12, 2019.
  4. ↑ Blankenship, Kyle (November 12, 2019). "Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?". FiercePharma.
  5. ↑ "Fortune: Viatris Company Profile, News, Rankings". Fortune.com. Fortune . Retrieved June 2, 2021.
  6. 1 2 Mamula, Kris B. (July 29, 2019). "Mylan merger with Pfizer's Upjohn unit to form new company with $20 billion in revenues". Pittsburgh Post-Gazette .
  7. ↑ "Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative" (Press release). PR Newswire. December 11, 2020.
  8. ↑ Gough, Paul J. (December 11, 2020). "Viatris to lay off up to 20% of global workforce, with local impacts expected to occur". American City Business Journals .
  9. ↑ Kansteiner, Fraiser (December 11, 2020). "Pfizer-Mylan combo Viatris to slash up to 9,000 jobs, shutter manufacturing plants in global cost-cutting drive". FiercePharma.
  10. ↑ "Viatris: 2021 Change the World". Fortune . Retrieved October 17, 2021.
  11. ↑ Linnane, Clara (February 28, 2022). "Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket". MarketWatch . Retrieved March 24, 2022.
  12. ↑ Priyan, Vishnu (November 30, 2022). "Biocon Biologics acquires biosimilars business of Viatris for $3bn". Pharmaceutical Technology.
  13. ↑ "Pittsburgh pharmaceutical company making its move into ophthalmology field". Pittsburgh Post-Gazette . November 7, 2022.
  14. ↑ Becker, Zoey (November 7, 2022). "Viatris jumps into ophthalmology arena with pair of buyouts worth up to $750M". Fierce Pharma.
  15. ↑ Sharma, Ruchika (January 4, 2023). "Viatris Closes Acquisitions Of Famy Life Sciences, Oyster Point Pharma To Establish Eye Care Division". Medical Dialogues.
  16. ↑ Gough, Paul J. (January 3, 2023). "Viatris completes 2 key acquisitions in vision care". Pittsburgh Business Times.
  17. ↑ Brier, Elisabeth (October 11, 2022). "World's Best Employers 2022". Forbes.
  18. ↑ Cooper, Nancy (2022). "America's Most Responsible Companies 2022". Newsweek.
  19. ↑ Rabkin Peachman, Rachel (October 10, 2023). "World's Best Employers". Forbes.
  20. ↑ Doughty, Nate (December 30, 2022). "Viatris appoints 2 new directors to its board". Pittsburgh Business Times.
  21. ↑ Tong, Goh Chiew (April 26, 2023). "Here are the top 25 companies to work for in India, according to LinkedIn — and most of them are not in tech". CNBC.com.
  22. ↑ O'Brien, Robert (April 20, 2023). "LinkedIn ranks Ireland's best employers for career development". Business Plus.
  23. ↑ Weise, Elizabeth (May 24, 2023). "Climate change calls for cuts in carbon emissions. These US companies are leading the way". USA Today.
  24. ↑ Murphy, Andrea; Tucker, Hank (June 8, 2023). "The Global 2000". Forbes.
  25. ↑ "Drugmaker Viatris to divest some businesses for $3.6 bln". Reuters. October 2, 2023.
  26. ↑ Levy, Sandra (November 16, 2020). "Viatris launches following combination of Mylan, Upjohn". Drug Store News. Retrieved May 6, 2021.
  27. ↑ Liu, Angus (April 23, 2021). "Merger of Mylan and Pfizer's Upjohn wins EU nod with product sell-off agreement". FiercePharma. Retrieved May 6, 2021.
  28. 1 2 Hagen, Tony (November 30, 2020). "Newly Created Viatris Joins the Biosimilars Forum". Centerforbiosimilars.com. Retrieved May 6, 2021.
  29. 1 2 "Viatris Inc. Joins Biosimilars Forum". Biosimilardevelopment.com. November 30, 2020. Retrieved May 6, 2021.
  30. ↑ Burton, Patrick (January 27, 2021). "Viatris: Cost-Cutting Needed at New Generics Behemoth". Pharmaboardroom.com. Retrieved May 6, 2021.
  31. ↑ Giuliani-Hoffman, Francesca (December 4, 2020). "HIV medications for children can be bitter to swallow. A strawberry-flavored drug might help". CNN . Retrieved June 13, 2021.
  32. ↑ "HIV generic drug for babies to be rolled out in Africa in 2021 - aid agencies". Reuters . December 1, 2020. Retrieved June 13, 2021.
  33. ↑ Genovese, Meghan (March 15, 2022). "FDA Grants Viatris Approval for Generic of Astra's Symbicort". Bloomberg Law.
  34. ↑ Hronec, Jordyn (March 16, 2022). "Viatris receives FDA approval for generic asthma drug". Pittsburgh Business Times.
  35. ↑ Shapiro, Lindsey (August 8, 2023). "FDA decision on GA Depot for relapsing MS expected March 2024". Multiple Sclerosis News Today.
  36. ↑ "FDA Accepts New Drug Application for GA Depot to Treat Relapsing Multiple Sclerosis". Practical Neurology. August 9, 2023.
  37. ↑ "FDA Provides Tentative Approval for HIV Therapy for Children". Contagion Live. September 5, 2023.
  38. ↑ Myshko, Denise (September 12, 2023). "Generic Triumeq PD, a First-line HIV Medication For Children, Gets Tentative OK". Managed Healthcare.
  39. ↑ Jackson Filkins, Kassi; Kaiser Maharjan, Emily (September 27, 2023). "FDA approves Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis". Optometry Times.
  40. ↑ "Fighting the Quiet Crisis of Noncommunicable Diseases". Scientific American Custom Media. January 27, 2021. Retrieved May 24, 2021.
  41. ↑ "NCD Academy". NCDalliance.org. March 20, 2020. Retrieved May 24, 2021.
  42. ↑ Kiner, Deb (December 7, 2020). "Sesame Workshop helps kids manage 'big feelings like stress and fear' with new resources". The Patriot-News . Retrieved May 24, 2021.
  43. ↑ "Sesame Workshop launches children's animations about COVID-19 education, resources for families". KGO-TV . December 7, 2020. Retrieved May 24, 2021.
  44. ↑ "Access to HIV self-tests significantly expanded and costs halved thanks to Unitaid agreement". Unitaid.org. April 28, 2021. Retrieved May 24, 2021.
  45. ↑ "HIV self-test prices to be slashed in half in 135 countries". PANCAP.org. April 29, 2021. Retrieved May 24, 2021.
  46. ↑ Levy, Sandra (March 7, 2024). "Viatris, Idorsia enter into global R&D collaboration". Drugstorenews.com.
  47. ↑ Bhattacharya, Nabaparna (February 28, 2024). "Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments". Benzinga.
  48. ↑ "Viatris and Idorsia Enter R&D Collaboration". Contractpharma.com. February 28, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.